glipizide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1301 29094-61-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • glypidizine
  • glidiazinamide
  • K 4024
  • K-4024
  • K4024
  • glipizide
  • dipazide
  • glibenese
  • glipizid
  • glucotrol
  • glucozide
  • glupizide
  • glydiazinamide
  • melizide
  • napizide
  • sucrazide
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
  • Molecular weight: 445.54
  • Formula: C21H27N5O4S
  • CLOGP: 2.60
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 130.15
  • ALOGS: -4.43
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.96 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.56 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.30 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 0.01 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,MAPK7,PDK1,PDK2,PIK3CB,PRKDC,TEK 15
kinase-selectivity-class GRK2 1
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 18.664 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
rat-kpuu-brain Rat brain Kpuu 0.013 % High 1

Approvals:

DateAgencyCompanyOrphan
May 8, 1984 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 800.48 12.22 502 38408 94744 90494793
Hypoglycaemia 563.61 12.22 359 38551 69489 90520048
Cardiac failure congestive 396.99 12.22 333 38577 98361 90491176
Blood glucose decreased 326.71 12.22 172 38738 23257 90566280
Myocardial infarction 244.54 12.22 263 38647 105709 90483828
Coronary artery disease 232.39 12.22 157 38753 33466 90556071
Diabetes mellitus inadequate control 168.05 12.22 103 38807 18581 90570956
Cerebrovascular accident 156.48 12.22 227 38683 123306 90466231
Lactic acidosis 133.82 12.22 135 38775 50328 90539209
Glycosylated haemoglobin increased 120.42 12.22 78 38832 15484 90574053
Product residue present 120.24 12.22 51 38859 4240 90585297
Infusion related reaction 119.93 12.22 18 38892 416762 90172775
Contraindicated product administered 109.83 12.22 7 38903 320132 90269405
Systemic lupus erythematosus 103.25 12.22 16 38894 361880 90227657
Synovitis 102.69 12.22 11 38899 329741 90259796
Glossodynia 102.11 12.22 10 38900 321769 90267768
Pericarditis 98.68 12.22 4 38906 270147 90319390
Blood glucose fluctuation 90.37 12.22 44 38866 5039 90584498
Exposure during pregnancy 82.39 12.22 5 38905 238405 90351132
Drug intolerance 82.12 12.22 45 38865 447546 90141991
Hypoglycaemic coma 81.99 12.22 35 38875 2955 90586582
Renal failure 80.06 12.22 175 38735 130832 90458705
Product complaint 79.13 12.22 57 38853 13443 90576094
Pancreatitis 77.92 12.22 121 38789 69705 90519832
Helicobacter infection 77.66 12.22 5 38905 226845 90362692
Off label use 76.61 12.22 232 38678 1102020 89487517
Lower respiratory tract infection 76.41 12.22 9 38901 250650 90338887
Wound 74.69 12.22 19 38891 302961 90286576
General physical health deterioration 73.89 12.22 30 38880 355085 90234452
Hyperglycaemia 70.88 12.22 98 38812 50872 90538665
Arthropathy 69.85 12.22 35 38875 366207 90223330
Rheumatoid arthritis 67.15 12.22 36 38874 362578 90226959
Acute kidney injury 66.42 12.22 293 38617 320094 90269443
Treatment failure 66.00 12.22 24 38886 303904 90285633
Blood glucose abnormal 64.78 12.22 44 38866 9448 90580089
Dehydration 63.74 12.22 206 38704 194241 90395296
Euglycaemic diabetic ketoacidosis 63.05 12.22 37 38873 6164 90583373
Joint swelling 63.05 12.22 74 38836 503226 90086311
Mental status changes 62.27 12.22 86 38824 44593 90544944
C-reactive protein increased 62.07 12.22 4 38906 181385 90408152
Diabetes mellitus 60.94 12.22 104 38806 64771 90524766
Irritable bowel syndrome 57.28 12.22 10 38900 207438 90382099
Completed suicide 57.21 12.22 164 38746 144894 90444643
Product dose omission issue 56.14 12.22 261 38649 291426 90298111
Discomfort 55.72 12.22 24 38886 274311 90315226
Diabetic ketoacidosis 55.21 12.22 60 38850 24347 90565190
Urinary tract infection 54.85 12.22 268 38642 305364 90284173
Hepatic enzyme increased 53.19 12.22 46 38864 360690 90228847
Product use issue 52.48 12.22 39 38871 329880 90259657
Musculoskeletal stiffness 51.24 12.22 32 38878 296500 90293037
Ischaemic cardiomyopathy 47.60 12.22 23 38887 2590 90586947
Diabetic neuropathy 45.74 12.22 27 38883 4547 90584990
Acute myocardial infarction 43.95 12.22 64 38846 34826 90554711
Death 42.99 12.22 339 38571 456212 90133325
Swelling 42.13 12.22 72 38838 418986 90170551
Thrombosis 41.52 12.22 95 38815 73156 90516381
Joint range of motion decreased 41.00 12.22 5 38905 135638 90453899
Impaired healing 40.83 12.22 25 38885 234174 90355363
Myocardial ischaemia 40.40 12.22 39 38871 13775 90575762
Psoriatic arthropathy 40.33 12.22 24 38886 228311 90361226
Chronic kidney disease 38.88 12.22 74 38836 50117 90539420
Chronic obstructive pulmonary disease 38.85 12.22 93 38817 73736 90515801
Cardiac disorder 38.21 12.22 79 38831 56793 90532744
Drug ineffective 37.65 12.22 397 38513 1383901 89205636
Alopecia 37.31 12.22 100 38810 494971 90094566
Bursitis 37.10 12.22 6 38904 131648 90457889
Asthenia 36.68 12.22 370 38540 533381 90056156
Cutaneous T-cell dyscrasia 36.48 12.22 8 38902 64 90589473
Pyrexia 36.39 12.22 153 38757 660332 89929205
Transient ischaemic attack 36.38 12.22 66 38844 43110 90546427
Fibromyalgia 35.98 12.22 22 38888 206247 90383290
Diarrhoea 35.22 12.22 582 38328 938608 89650929
Liver injury 34.49 12.22 15 38895 170552 90418985
Nausea 33.54 12.22 665 38245 1109651 89479886
Nodular rash 32.61 12.22 9 38901 199 90589338
Oedema peripheral 32.11 12.22 205 38705 257710 90331827
Atrial fibrillation 31.36 12.22 127 38783 133484 90456053
Pancreatitis acute 30.83 12.22 52 38858 32063 90557474
Gout 30.62 12.22 37 38873 16822 90572715
Weight decreased 30.36 12.22 272 38638 379638 90209899
Mobility decreased 30.14 12.22 38 38872 250696 90338841
Cellulitis 30.11 12.22 97 38813 91240 90498297
Hypoacusis 29.31 12.22 47 38863 27803 90561734
Grip strength decreased 29.01 12.22 3 38907 92573 90496964
Gastrointestinal haemorrhage 28.99 12.22 95 38815 90153 90499384
Ventricular hypertrophy 28.73 12.22 18 38892 3373 90586164
Inflammation 28.52 12.22 21 38889 178571 90410966
Therapeutic product effect decreased 28.51 12.22 47 38863 277524 90312013
Blister 28.27 12.22 41 38869 254957 90334580
Renal injury 28.24 12.22 28 38882 10215 90579322
Chest pain 28.22 12.22 234 38676 319411 90270126
Ill-defined disorder 27.93 12.22 23 38887 184868 90404669
Lung disorder 27.54 12.22 15 38895 149868 90439669
Stool analysis abnormal 27.36 12.22 6 38904 48 90589489
Toxicity to various agents 27.19 12.22 214 38696 287632 90301905
Stomatitis 26.85 12.22 48 38862 274650 90314887
Coronary artery occlusion 26.63 12.22 25 38885 8529 90581008
Rhabdomyolysis 26.35 12.22 64 38846 51192 90538345
Intentional product use issue 25.93 12.22 33 38877 216859 90372678
Condition aggravated 25.30 12.22 151 38759 595394 89994143
Acute coronary syndrome 25.19 12.22 27 38883 10786 90578751
Cardiovascular disorder 25.14 12.22 30 38880 13462 90576075
Fall 24.48 12.22 315 38595 481495 90108042
Plasma cell myeloma 24.30 12.22 54 38856 40774 90548763
Cardiac arrest 24.03 12.22 99 38811 104836 90484701
Hypersensitivity 23.98 12.22 107 38803 454570 90134967
Infection 23.74 12.22 78 38832 362016 90227521
Vision blurred 23.66 12.22 102 38808 110191 90479346
Acute respiratory failure 23.59 12.22 55 38855 42863 90546674
Emotional distress 23.55 12.22 50 38860 36612 90552925
Pernicious anaemia 23.41 12.22 10 38900 846 90588691
Gastrointestinal disorder 23.20 12.22 47 38863 256640 90332897
Wheezing 22.91 12.22 42 38868 238038 90351499
Product appearance confusion 22.70 12.22 6 38904 112 90589425
Epilepsy 22.60 12.22 4 38906 82202 90507335
Abdominal discomfort 22.45 12.22 117 38793 477211 90112326
Hyperlipidaemia 21.86 12.22 37 38873 22879 90566658
Hypercholesterolaemia 21.82 12.22 8 38902 100884 90488653
Sepsis 21.79 12.22 142 38768 179672 90409865
Hyperinsulinaemic hypoglycaemia 21.56 12.22 6 38904 137 90589400
International normalised ratio increased 21.12 12.22 56 38854 47260 90542277
Knee arthroplasty 20.90 12.22 5 38905 83177 90506360
Haemorrhage intracranial 20.84 12.22 29 38881 15133 90574404
Sleep disorder 20.83 12.22 33 38877 197997 90391540
Haemodialysis 20.65 12.22 22 38888 8725 90580812
Unevaluable event 20.63 12.22 61 38849 54787 90534750
Dilatation atrial 20.61 12.22 12 38898 1969 90587568
Angina unstable 20.57 12.22 20 38890 7123 90582414
Wound infection 20.51 12.22 10 38900 106392 90483145
Blood potassium increased 20.46 12.22 34 38876 20715 90568822
Hip arthroplasty 20.32 12.22 4 38906 76204 90513333
Ventricular dysfunction 20.16 12.22 15 38895 3716 90585821
Blood urea increased 20.14 12.22 42 38868 30371 90559166
Dizziness 20.13 12.22 360 38550 588924 90000613
Cardiomegaly 20.00 12.22 32 38878 18893 90570644
Injection site nodule 19.84 12.22 16 38894 4457 90585080
Drug-induced liver injury 19.81 12.22 7 38903 90311 90499226
Migraine 19.76 12.22 32 38878 190360 90399177
Hyperkalaemia 19.63 12.22 67 38843 64897 90524640
Flatulence 19.53 12.22 50 38860 41317 90548220
Hypervolaemia 19.13 12.22 43 38867 32714 90556823
Drug interaction 19.11 12.22 192 38718 276261 90313276
Treatment noncompliance 18.95 12.22 57 38853 51670 90537867
Therapeutic product effect incomplete 18.83 12.22 34 38876 193862 90395675
Fear 18.80 12.22 29 38881 16593 90572944
Essential hypertension 18.79 12.22 18 38892 6297 90583240
Autoimmune disorder 18.53 12.22 5 38905 76739 90512798
Respiratory failure 18.52 12.22 100 38810 118318 90471219
Nasopharyngitis 18.46 12.22 101 38809 407003 90182534
Blood creatinine increased 18.21 12.22 89 38821 101297 90488240
Pancreatic carcinoma 17.92 12.22 20 38890 8357 90581180
Product use in unapproved indication 17.79 12.22 79 38831 336157 90253380
Anhedonia 17.44 12.22 23 38887 11408 90578129
Adenocarcinoma pancreas 17.43 12.22 9 38901 1167 90588370
Suspected suicide 17.38 12.22 21 38889 9547 90579990
Haemoglobin decreased 17.30 12.22 124 38786 161832 90427705
Pancytopenia 17.11 12.22 99 38811 120164 90469373
Pregnancy 17.10 12.22 3 38907 62044 90527493
Renal disorder 17.09 12.22 45 38865 37814 90551723
Blood triglycerides increased 16.98 12.22 25 38885 13736 90575801
Hyperinsulinaemia 16.89 12.22 5 38905 143 90589394
Pulmonary hypertension 16.67 12.22 48 38862 42475 90547062
Peripheral vascular disorder 16.66 12.22 17 38893 6414 90583123
Arthralgia 16.59 12.22 235 38675 778287 89811250
Dysgeusia 16.58 12.22 55 38855 52505 90537032
Platelet count decreased 16.49 12.22 108 38802 136861 90452676
Glucose urine present 16.43 12.22 8 38902 916 90588621
Liver function test increased 16.31 12.22 8 38902 84847 90504690
Prescribed overdose 16.21 12.22 11 38899 97614 90491923
Night sweats 16.01 12.22 19 38891 128747 90460790
Peripheral venous disease 16.00 12.22 8 38902 83913 90505624
Pancreatitis haemorrhagic 15.85 12.22 7 38903 642 90588895
Arteriosclerosis coronary artery 15.71 12.22 20 38890 9583 90579954
Lipid metabolism disorder 15.66 12.22 5 38905 185 90589352
Coronary artery stenosis 15.65 12.22 15 38895 5251 90584286
White blood cell count decreased 15.63 12.22 124 38786 166985 90422552
Red blood cell sedimentation rate increased 15.56 12.22 8 38902 82587 90506950
Hypophagia 15.50 12.22 42 38868 35895 90553642
Visual acuity reduced 15.12 12.22 32 38878 23378 90566159
Diabetic retinopathy 14.91 12.22 11 38899 2691 90586846
Hepatitis 14.65 12.22 6 38904 70733 90518804
Blepharospasm 14.60 12.22 3 38907 55442 90534095
Dyspnoea 14.48 12.22 487 38423 880468 89709069
Colitis ulcerative 14.41 12.22 4 38906 60262 90529275
Anaemia 14.40 12.22 222 38688 352580 90236957
Foot deformity 14.19 12.22 4 38906 59647 90529890
Therapy non-responder 14.16 12.22 23 38887 136681 90452856
Laryngeal pain 13.91 12.22 13 38897 4409 90585128
Mitral valve incompetence 13.64 12.22 30 38880 22494 90567043
Hypoglycaemic seizure 13.54 12.22 6 38904 554 90588983
Leukopenia 13.46 12.22 14 38896 100696 90488841
Nephrolithiasis 13.43 12.22 49 38861 49036 90540501
Pulmonary fibrosis 13.22 12.22 16 38894 107487 90482050
Suicide attempt 13.20 12.22 8 38902 75391 90514146
Dialysis 13.15 12.22 20 38890 11309 90578228
Taste disorder 13.11 12.22 5 38905 61541 90527996
Prescribed underdose 13.07 12.22 8 38902 75011 90514526
Hunger 12.90 12.22 15 38895 6548 90582989
Incorrect route of product administration 12.80 12.22 3 38907 50623 90538914
Drug abuse 12.73 12.22 10 38900 82337 90507200
Catheterisation cardiac 12.66 12.22 13 38897 4943 90584594
Musculoskeletal pain 12.56 12.22 35 38875 171216 90418321
Gastritis 12.56 12.22 43 38867 41710 90547827
Sciatica 12.56 12.22 15 38895 101367 90488170
Angioedema 12.41 12.22 58 38852 64818 90524719
Necrobiosis lipoidica diabeticorum 12.36 12.22 3 38907 39 90589498
Body height decreased 12.35 12.22 20 38890 11929 90577608
Myalgia 12.27 12.22 122 38788 175003 90414534

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 833.78 11.90 584 40123 59270 42521358
Blood glucose increased 578.75 11.90 513 40194 73186 42507442
Cardiac failure congestive 342.31 11.90 415 40292 85187 42495441
Myocardial infarction 313.17 11.90 481 40226 123528 42457100
Completed suicide 222.29 11.90 359 40348 96106 42484522
Blood glucose decreased 216.93 11.90 147 40560 14072 42566556
Coronary artery disease 202.49 11.90 253 40454 53467 42527161
Off label use 138.41 11.90 250 40457 638085 41942543
Glycosylated haemoglobin increased 99.24 11.90 89 40618 12835 42567793
Cerebrovascular accident 98.95 11.90 258 40449 96902 42483726
Pancreatitis 75.97 11.90 143 40564 43125 42537503
Drug abuse 69.49 11.90 9 40698 104762 42475866
Diabetes mellitus inadequate control 65.26 11.90 77 40630 15313 42565315
Product complaint 64.24 11.90 50 40657 5927 42574701
Febrile neutropenia 62.99 11.90 51 40656 185652 42394976
Product use in unapproved indication 57.33 11.90 55 40652 184401 42396227
Mental status changes 55.91 11.90 124 40583 41991 42538637
Myocardial ischaemia 53.48 11.90 75 40632 17687 42562941
Injury 51.20 11.90 83 40624 22233 42558395
Blood glucose abnormal 51.06 11.90 47 40660 7006 42573622
General physical health deterioration 49.47 11.90 43 40664 151203 42429425
Ischaemic cardiomyopathy 46.32 11.90 43 40664 6479 42574149
Product residue present 44.81 11.90 30 40677 2811 42577817
Cardiac disorder 43.81 11.90 124 40583 48808 42531820
Diabetic neuropathy 42.70 11.90 35 40672 4467 42576161
Neutropenia 37.84 11.90 84 40623 199347 42381281
C-reactive protein increased 36.53 11.90 8 40699 63552 42517076
Drug ineffective 36.52 11.90 406 40301 629791 41950837
Cardiovascular disorder 35.24 11.90 53 40654 13312 42567316
Blood glucose fluctuation 34.05 11.90 31 40676 4556 42576072
Diabetic ketoacidosis 33.29 11.90 69 40638 22298 42558330
Myasthenic syndrome 33.04 11.90 16 40691 805 42579823
Interstitial lung disease 32.76 11.90 17 40690 78445 42502183
Spur cell anaemia 31.06 11.90 8 40699 56 42580572
Hypophagia 30.97 11.90 75 40632 26881 42553747
Asthenia 30.78 11.90 406 40301 280387 42300241
Acute myocardial infarction 30.38 11.90 123 40584 58042 42522586
Autoimmune myocarditis 30.35 11.90 11 40696 264 42580364
Pyrexia 29.99 11.90 237 40470 393805 42186823
Emotional distress 29.24 11.90 54 40653 16039 42564589
Lactic acidosis 28.84 11.90 102 40605 45159 42535469
Type 2 diabetes mellitus 28.69 11.90 58 40649 18413 42562215
Pancreatitis acute 27.10 11.90 82 40625 33482 42547146
Angina unstable 26.83 11.90 43 40664 11405 42569223
Unresponsive to stimuli 25.62 11.90 77 40630 31326 42549302
Myelosuppression 25.59 11.90 4 40703 40457 42540171
Glycosylated haemoglobin abnormal 25.56 11.90 10 40697 298 42580330
Condition aggravated 24.15 11.90 148 40559 260606 42320022
Treatment failure 22.74 11.90 16 40691 62608 42518020
Transient ischaemic attack 22.32 11.90 77 40630 33662 42546966
Diabetes mellitus 21.67 11.90 114 40593 59973 42520655
Hyperglycaemia 21.62 11.90 94 40613 45765 42534863
Bladder cancer 21.28 11.90 49 40658 16998 42563630
Product dose omission issue 21.16 11.90 233 40474 154132 42426496
Anhedonia 21.15 11.90 31 40676 7609 42573019
Renal injury 20.81 11.90 40 40667 12240 42568388
Drug resistance 20.31 11.90 4 40703 34244 42546384
Leukopenia 20.18 11.90 25 40682 74721 42505907
Peripheral vascular disorder 19.93 11.90 25 40682 5292 42575336
Agranulocytosis 19.42 11.90 3 40704 30609 42550019
Renal failure 19.27 11.90 216 40491 143510 42437118
Chest pain 18.84 11.90 210 40497 139320 42441308
Product quality issue 18.69 11.90 48 40659 17834 42562794
Drug intolerance 18.63 11.90 30 40677 80394 42500234
Arteriosclerosis 18.51 11.90 48 40659 17941 42562687
Gastrointestinal mucosal necrosis 18.50 11.90 7 40700 190 42580438
International normalised ratio increased 18.49 11.90 93 40614 48075 42532553
Weight decreased 18.49 11.90 290 40417 207658 42372970
Fatigue 18.12 11.90 544 40163 435097 42145531
Cytokine release syndrome 18.07 11.90 10 40697 44517 42536111
Poor quality product administered 17.92 11.90 16 40691 2292 42578336
Interstitial granulomatous dermatitis 17.85 11.90 7 40700 210 42580418
Dizziness 17.62 11.90 335 40372 248919 42331709
Cardiomyopathy 17.49 11.90 49 40658 19161 42561467
Mucosal inflammation 17.42 11.90 13 40694 49361 42531267
Intentional product use issue 17.40 11.90 26 40681 71807 42508821
Lower respiratory tract infection 17.09 11.90 9 40698 41197 42539431
Distributive shock 16.85 11.90 16 40691 2480 42578148
Acute kidney injury 16.71 11.90 464 40243 366873 42213755
Drug ineffective for unapproved indication 16.49 11.90 12 40695 46151 42534477
Pancreatic carcinoma 16.15 11.90 31 40676 9475 42571153
Therapeutic product effect incomplete 15.93 11.90 27 40680 70912 42509716
Diverticulum 15.89 11.90 27 40680 7514 42573114
Glycosylated haemoglobin decreased 15.87 11.90 8 40699 439 42580189
Product use issue 15.65 11.90 31 40676 76720 42503908
Coronary artery occlusion 15.29 11.90 33 40674 10964 42569664
Cytomegalovirus infection 15.04 11.90 6 40701 32300 42548328
Eczema 14.80 11.90 7 40700 34079 42546549
COVID-19 14.62 11.90 59 40648 115889 42464739
Neutrophil count decreased 14.37 11.90 24 40683 63391 42517237
Altered state of consciousness 14.35 11.90 5 40702 29254 42551374
Vision blurred 14.26 11.90 94 40613 53605 42527023
Thrombocytopenia 14.16 11.90 115 40592 190164 42390464
Suicide attempt 14.00 11.90 14 40693 46086 42534542
Chronic kidney disease 13.97 11.90 85 40622 47156 42533472
Fall 13.86 11.90 307 40400 234213 42346415
Electrocardiogram ST-T change 13.64 11.90 8 40699 594 42580034
Acute coronary syndrome 13.62 11.90 38 40669 14827 42565801
Anaphylactic shock 13.43 11.90 3 40704 23514 42557114
Blood loss anaemia 13.29 11.90 29 40678 9707 42570921
Hyperkalaemia 13.18 11.90 126 40581 80332 42500296
Fear 13.12 11.90 31 40676 10934 42569694
Tachycardia 13.02 11.90 51 40656 101036 42479592
Occult blood positive 12.85 11.90 18 40689 4239 42576389
Suspected suicide 12.80 11.90 22 40685 6177 42574451
Dehydration 12.70 11.90 198 40509 141569 42439059
Arteriosclerosis coronary artery 12.68 11.90 43 40664 18634 42561994
Renal disorder 12.60 11.90 58 40649 28922 42551706
Blood pressure fluctuation 12.52 11.90 5 40702 26903 42553725
Multiple injuries 12.47 11.90 12 40695 1890 42578738
Cholestasis 12.47 11.90 8 40699 32871 42547757
Hyphaema 12.32 11.90 8 40699 712 42579916
Pancreatic carcinoma metastatic 12.05 11.90 15 40692 3151 42577477
Infusion related reaction 12.02 11.90 25 40682 60781 42519847
Blood creatinine increased 11.98 11.90 159 40548 109844 42470784
Human anaplasmosis 11.96 11.90 4 40703 75 42580553
Cellulitis 11.91 11.90 100 40607 61485 42519143

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 1428.53 11.88 860 61253 115244 110411942
Blood glucose increased 964.62 11.88 708 61405 131788 110395398
Cardiac failure congestive 627.71 11.88 583 61530 150417 110376769
Myocardial infarction 588.28 11.88 628 61485 191455 110335731
Blood glucose decreased 421.29 11.88 241 61872 29247 110497939
Coronary artery disease 388.37 11.88 322 61791 71368 110455818
Completed suicide 348.48 11.88 545 61568 241836 110285350
Cerebrovascular accident 244.37 11.88 396 61717 180888 110346298
Lactic acidosis 171.28 11.88 235 61878 92576 110434610
Glycosylated haemoglobin increased 166.52 11.88 124 61989 23495 110503691
Off label use 158.54 11.88 384 61729 1499801 109027385
Diabetes mellitus inadequate control 129.36 11.88 118 61995 29657 110497529
Product residue present 123.94 11.88 55 62058 3886 110523300
Mental status changes 120.22 11.88 179 61934 75943 110451243
Infusion related reaction 114.16 11.88 36 62077 381126 110146060
Synovitis 111.49 11.88 12 62101 274080 110253106
Drug intolerance 108.89 11.88 46 62067 406466 110120720
Hand deformity 108.71 11.88 3 62110 218503 110308683
Acute kidney injury 103.41 11.88 660 61453 634770 109892416
General physical health deterioration 103.37 11.88 55 62058 425240 110101946
Pancreatitis 99.32 11.88 184 61929 93349 110433837
Ischaemic cardiomyopathy 97.37 11.88 59 62054 7952 110519234
Contraindicated product administered 95.72 11.88 13 62100 248254 110278932
Acute myocardial infarction 95.54 11.88 170 61943 83607 110443579
Product complaint 95.47 11.88 72 62041 13900 110513286
Systemic lupus erythematosus 91.95 11.88 16 62097 254322 110272864
Lower respiratory tract infection 90.78 11.88 14 62099 243092 110284094
Death 90.77 11.88 687 61426 698182 109829004
Pericarditis 90.63 11.88 9 62104 219105 110308081
Myocardial ischaemia 88.17 11.88 91 62022 26593 110500593
C-reactive protein increased 84.99 11.88 11 62102 217908 110309278
Rheumatoid arthritis 84.99 11.88 31 62082 299582 110227604
Cardiac disorder 82.16 11.88 151 61962 76129 110451057
Helicobacter infection 82.14 11.88 5 62108 181872 110345314
Blood glucose abnormal 80.46 11.88 63 62050 12853 110514333
Hyperglycaemia 80.02 11.88 159 61954 84931 110442255
Drug ineffective 79.48 11.88 515 61598 1520025 109007161
Renal failure 78.83 11.88 293 61820 226281 110300905
Diabetic ketoacidosis 78.32 11.88 107 62006 41951 110485235
Glossodynia 78.02 11.88 15 62098 221989 110305197
Treatment failure 76.43 11.88 30 62083 277204 110249982
Hypoglycaemic coma 75.74 11.88 44 62069 5489 110521697
Euglycaemic diabetic ketoacidosis 75.24 11.88 58 62055 11565 110515621
Blood glucose fluctuation 71.88 11.88 48 62065 7650 110519536
Diabetic neuropathy 71.09 11.88 46 62067 6953 110520233
Arthropathy 70.09 11.88 37 62076 287485 110239701
Irritable bowel syndrome 67.24 11.88 7 62106 164208 110362978
Product use in unapproved indication 64.07 11.88 95 62018 447282 110079904
Dehydration 63.67 11.88 318 61795 279193 110247993
Product dose omission issue 62.29 11.88 350 61763 321432 110205754
Cardiovascular disorder 61.84 11.88 70 62043 22690 110504496
Diabetes mellitus 59.20 11.88 155 61958 99226 110427960
Musculoskeletal stiffness 58.54 11.88 43 62070 279779 110247407
Wound 57.38 11.88 30 62083 234407 110292779
Fibromyalgia 57.06 11.88 13 62100 170896 110356290
Transient ischaemic attack 55.92 11.88 116 61997 63866 110463320
Drug abuse 54.44 11.88 16 62097 177395 110349791
Angina unstable 54.21 11.88 56 62057 16376 110510810
Asthenia 53.62 11.88 607 61506 688392 109838794
Inflammation 53.10 11.88 21 62092 193217 110333969
Joint swelling 52.48 11.88 106 62007 442739 110084447
Hypophagia 51.48 11.88 100 62013 52526 110474660
Product use issue 50.92 11.88 60 62053 311635 110215551
Rhabdomyolysis 48.99 11.88 164 61949 120237 110406949
International normalised ratio increased 48.32 11.88 132 61981 86640 110440546
Hyperkalaemia 47.52 11.88 176 61937 135620 110391566
Psoriatic arthropathy 46.95 11.88 26 62087 196735 110330451
Pyrexia 46.84 11.88 304 61809 897961 109629225
Chronic obstructive pulmonary disease 46.48 11.88 151 61962 109007 110418179
Impaired healing 45.50 11.88 27 62086 196690 110330496
Atrial fibrillation 45.22 11.88 251 61862 229391 110297795
Alopecia 45.21 11.88 85 62028 364668 110162518
Gastrointestinal haemorrhage 44.75 11.88 198 61915 165320 110361866
Pancreatitis acute 44.39 11.88 102 62011 60172 110467014
Bursitis 43.13 11.88 10 62103 129908 110397278
Unresponsive to stimuli 42.69 11.88 104 62009 63686 110463500
Coronary artery occlusion 41.98 11.88 48 62065 15724 110511462
Lip dry 41.66 11.88 4 62109 100079 110427107
Intentional product use issue 41.26 11.88 47 62066 247859 110279327
Lung disorder 41.23 11.88 25 62088 180022 110347164
Emotional distress 41.19 11.88 83 62030 44764 110482422
Chest pain 41.11 11.88 356 61757 376019 110151167
Ill-defined disorder 39.99 11.88 19 62094 156834 110370352
Bladder cancer 39.87 11.88 53 62060 20239 110506947
Epilepsy 39.20 11.88 5 62108 100204 110426982
Acute coronary syndrome 38.86 11.88 56 62057 23056 110504130
Renal injury 38.51 11.88 50 62063 18663 110508523
Hepatic enzyme increased 37.83 11.88 77 62036 320815 110206371
Infection 37.74 11.88 93 62020 362107 110165079
Discomfort 37.62 11.88 39 62074 214668 110312518
Febrile neutropenia 37.36 11.88 76 62037 316691 110210495
Peripheral vascular disorder 37.27 11.88 34 62079 8542 110518644
Therapeutic product effect decreased 36.80 11.88 50 62063 244266 110282920
Condition aggravated 36.61 11.88 252 61861 734584 109792602
Cellulitis 36.56 11.88 154 61959 125862 110401324
Gastrointestinal disorder 35.96 11.88 50 62063 241902 110285284
Hypoacusis 35.80 11.88 68 62045 35123 110492063
Suspected suicide 35.07 11.88 43 62070 15156 110512030
Sleep disorder 34.90 11.88 36 62077 198608 110328578
Cutaneous T-cell dyscrasia 34.56 11.88 8 62105 62 110527124
Myasthenic syndrome 34.41 11.88 16 62097 1260 110525926
Myelosuppression 33.94 11.88 6 62107 94334 110432852
Treatment noncompliance 33.85 11.88 104 62009 72886 110454300
Chronic kidney disease 33.80 11.88 107 62006 76184 110451002
Cardiac arrest 32.88 11.88 206 61907 196547 110330639
Joint range of motion decreased 32.24 11.88 14 62099 121818 110405368
Arteriosclerosis 31.82 11.88 53 62060 24714 110502472
Urinary tract infection 31.73 11.88 301 61812 325981 110201205
Stomatitis 31.72 11.88 65 62048 270177 110257009
Liver injury 31.59 11.88 23 62090 150390 110376796
Therapeutic product effect incomplete 31.54 11.88 48 62065 223757 110303429
Blood creatinine increased 31.51 11.88 193 61920 182696 110344490
Mobility decreased 31.50 11.88 53 62060 237369 110289817
Arteriosclerosis coronary artery 29.96 11.88 52 62061 25066 110502120
Anhedonia 29.86 11.88 40 62073 15388 110511798
Spur cell anaemia 29.41 11.88 8 62105 126 110527060
Migraine 29.15 11.88 32 62081 171620 110355566
Blister 29.03 11.88 52 62061 227324 110299862
Plasma cell myeloma 28.55 11.88 89 62024 62847 110464339
Fall 27.90 11.88 485 61628 602997 109924189
Drug reaction with eosinophilia and systemic symptoms 27.89 11.88 6 62107 82089 110445097
Oedema peripheral 27.06 11.88 293 61820 328367 110198819
Haemodialysis 27.01 11.88 41 62072 17678 110509508
Hypersensitivity 26.87 11.88 126 61987 403872 110123314
Autoimmune myocarditis 26.81 11.88 11 62102 640 110526546
Arthralgia 26.53 11.88 295 61818 779337 109747849
Essential hypertension 26.35 11.88 27 62086 7820 110519366
Glycosylated haemoglobin abnormal 26.32 11.88 10 62103 474 110526712
Autoimmune disorder 26.27 11.88 3 62110 65480 110461706
Cardiomyopathy 26.09 11.88 58 62055 33467 110493719
Nodular rash 25.97 11.88 9 62104 327 110526859
Occult blood positive 25.70 11.88 26 62087 7419 110519767
Wheezing 25.44 11.88 67 62046 255163 110272023
Angioedema 25.24 11.88 116 61997 98384 110428802
Mitral valve incompetence 25.20 11.88 57 62056 33272 110493914
Myopathy 25.11 11.88 48 62065 24912 110502274
Fear 25.07 11.88 46 62067 23147 110504039
Peripheral venous disease 25.05 11.88 8 62105 84109 110443077
Dizziness 24.77 11.88 539 61574 697654 109829532
Frequent bowel movements 24.70 11.88 5 62108 71385 110455801
Weight decreased 24.51 11.88 384 61729 467673 110059513
Thrombosis 24.26 11.88 123 61990 108539 110418647
Wound infection 24.11 11.88 12 62101 96453 110430733
Swelling 23.62 11.88 109 62004 350932 110176254
Vision blurred 23.39 11.88 138 61975 128884 110398302
Poor quality product administered 23.36 11.88 20 62093 4621 110522565
Musculoskeletal pain 23.23 11.88 42 62071 182981 110344205
Sinusitis 23.15 11.88 87 62026 296601 110230585
Nasopharyngitis 22.83 11.88 129 61984 394232 110132954
Stool analysis abnormal 22.65 11.88 7 62106 176 110527010
Unevaluable event 22.61 11.88 79 62034 59148 110468038
Dialysis 22.60 11.88 40 62073 19579 110507607
Liver disorder 22.56 11.88 28 62085 142215 110384971
Blood pressure fluctuation 22.49 11.88 7 62106 74817 110452369
Toxicity to various agents 22.11 11.88 386 61727 480169 110047017
Blood potassium increased 22.02 11.88 54 62059 33195 110493991
Drug-induced liver injury 21.95 11.88 21 62092 120046 110407140
Gamma-glutamyltransferase increased 21.83 11.88 4 62109 61305 110465881
Interstitial lung disease 21.50 11.88 28 62085 139306 110387880
Ventricular hypertrophy 21.44 11.88 23 62090 7022 110520164
Blood loss anaemia 21.08 11.88 37 62076 17988 110509198
Haemoglobin decreased 21.05 11.88 223 61890 248504 110278682
Gastrointestinal mucosal necrosis 20.84 11.88 7 62106 231 110526955
Blepharospasm 20.83 11.88 3 62110 54848 110472338
Toe amputation 20.44 11.88 18 62095 4320 110522866
Hyperlipidaemia 20.41 11.88 55 62058 35793 110491393
Colitis ulcerative 20.29 11.88 9 62104 77354 110449832
Dilatation atrial 20.21 11.88 17 62096 3835 110523351
Agranulocytosis 20.01 11.88 5 62108 61755 110465431
Gout 19.73 11.88 55 62058 36511 110490675
Hyperinsulinaemic hypoglycaemia 19.44 11.88 7 62106 285 110526901
Drug resistance 19.39 11.88 4 62109 56370 110470816
Interstitial granulomatous dermatitis 19.39 11.88 7 62106 287 110526899
Diabetic retinopathy 19.26 11.88 16 62097 3548 110523638
Hypervolaemia 18.91 11.88 66 62047 49394 110477792
Syncope 18.76 11.88 185 61928 202351 110324835
Osteoporosis 18.72 11.88 13 62100 87139 110440047
Pernicious anaemia 18.71 11.88 9 62104 765 110526421
Coronary artery stenosis 18.43 11.88 30 62083 13728 110513458
Neutropenia 18.35 11.88 129 61984 374491 110152695
Taste disorder 18.13 11.88 7 62106 65380 110461806
Leukopenia 18.13 11.88 35 62078 148756 110378430
Prescribed underdose 18.03 11.88 7 62106 65167 110462019
Product solubility abnormal 17.95 11.88 10 62103 1152 110526034
Asthma 17.87 11.88 76 62037 250215 110276971
Incorrect route of product administration 17.53 11.88 7 62106 64054 110463132
Therapy non-responder 17.48 11.88 39 62074 157268 110369918
Acute respiratory failure 17.37 11.88 86 62027 75174 110452012
Hip arthroplasty 17.18 11.88 5 62108 55808 110471378
Loss of consciousness 17.07 11.88 177 61936 196129 110331057
Multiple injuries 17.03 11.88 15 62098 3599 110523587
Right ventricular failure 17.03 11.88 42 62071 25912 110501274
Cardiomegaly 16.90 11.88 45 62068 29085 110498101
Suicide attempt 16.76 11.88 20 62093 103374 110423812
Cytomegalovirus infection 16.53 11.88 5 62108 54439 110472747
Carotid artery stenosis 16.39 11.88 23 62090 9240 110517946
Cognitive disorder 16.36 11.88 15 62098 87496 110439690
Product physical issue 16.32 11.88 17 62096 5019 110522167
Obesity 16.26 11.88 24 62089 113327 110413859
High density lipoprotein decreased 16.20 11.88 18 62095 5715 110521471
Cholestasis 16.16 11.88 8 62105 64510 110462676
Nausea 16.13 11.88 848 61265 1234842 109292344
Glucose urine present 16.09 11.88 12 62101 2277 110524909
Haemorrhage intracranial 16.05 11.88 44 62069 28925 110498261
Osteoarthritis 15.96 11.88 51 62062 182572 110344614
Hyperinsulinaemia 15.86 11.88 6 62107 281 110526905
Cytokine release syndrome 15.76 11.88 10 62103 70296 110456890
Hyphaema 15.67 11.88 9 62104 1098 110526088
Laryngeal pain 15.59 11.88 18 62095 5957 110521229
Cardio-respiratory arrest 15.59 11.88 115 61998 115721 110411465
Haematocrit decreased 15.58 11.88 76 62037 66041 110461145
Abdominal discomfort 15.44 11.88 144 61969 393714 110133472
Eczema 15.25 11.88 11 62102 72282 110454904
Lower limb fracture 15.20 11.88 12 62101 75336 110451850
Anaphylactic shock 15.18 11.88 5 62108 51541 110475645
Full blood count decreased 15.12 11.88 46 62067 32053 110495133
Deep vein thrombosis 15.08 11.88 132 61981 139755 110387431
Blood urea increased 15.04 11.88 66 62047 54891 110472295
Tricuspid valve incompetence 15.00 11.88 38 62075 23835 110503351
Angina pectoris 14.96 11.88 72 62041 62223 110464963
Electrocardiogram ST-T change 14.94 11.88 10 62103 1600 110525586
Sciatica 14.85 11.88 18 62095 92381 110434805
Nail disorder 14.79 11.88 7 62106 57928 110469258
Renal disorder 14.76 11.88 61 62052 49418 110477768
Drug ineffective for unapproved indication 14.53 11.88 22 62091 102816 110424370
Diarrhoea 14.46 11.88 780 61333 1138725 109388461
Pulmonary fibrosis 14.26 11.88 22 62091 102020 110425166
Night sweats 14.25 11.88 34 62079 133949 110393237
Dyspnoea 14.11 11.88 758 61355 1106114 109421072
Distributive shock 14.10 11.88 17 62096 5887 110521299
Fluid retention 14.07 11.88 96 62017 94211 110432975
Hypoglycaemic seizure 14.02 11.88 8 62105 964 110526222
Red blood cell sedimentation rate increased 13.96 11.88 14 62099 78288 110448898
Respiratory failure 13.77 11.88 183 61930 215149 110312037
Dysgeusia 13.43 11.88 76 62037 69909 110457277
Acidosis 13.27 11.88 35 62078 22496 110504690
Lethargy 13.22 11.88 94 62019 93482 110433704
Human anaplasmosis 13.12 11.88 4 62109 96 110527090
Pancreatic carcinoma 13.03 11.88 27 62086 14845 110512341
Inadequate analgesia 12.76 11.88 15 62098 5062 110522124
Sinus tachycardia 12.61 11.88 54 62059 44439 110482747
Product appearance confusion 12.43 11.88 4 62109 115 110527071
Ventricular dysfunction 12.34 11.88 18 62095 7493 110519693
Knee arthroplasty 12.30 11.88 11 62102 64937 110462249
Hypercholesterolaemia 12.30 11.88 20 62093 90817 110436369
Delirium 12.30 11.88 37 62076 134988 110392198
Ketoacidosis 12.18 11.88 21 62092 10066 110517120
Wrong product administered 12.18 11.88 22 62091 10938 110516248
Foot deformity 12.16 11.88 6 62107 48474 110478712
Prescribed overdose 12.12 11.88 19 62094 87562 110439624
Glycosylated haemoglobin decreased 12.11 11.88 7 62106 865 110526321
Hepatitis 12.03 11.88 20 62093 90034 110437152
Blood sodium decreased 12.03 11.88 48 62065 38271 110488915
Mitral valve calcification 12.02 11.88 9 62104 1719 110525467
Pulmonary hypertension 11.97 11.88 62 62051 55158 110472028
Blood triglycerides increased 11.95 11.88 35 62078 23891 110503295
Adenocarcinoma pancreas 11.90 11.88 10 62103 2253 110524933

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BB07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sulfonylureas
FDA CS M0020795 Sulfonylurea Compounds
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:77194 EC 2.7.1.33 (pantothenate kinase) inhibitor
CHEBI has role CHEBI:90415 insulin secretagogue
CHEBI has role CHEBI:145947 antiatherosclerotic agent
FDA EPC N0000175608 Sulfonylurea

Related Drugs by ATC class:

A10BB Sulfonylureas 12 drugs
acetohexamidecarbutamidechlorpropamideglibenclamideglibornuridegliclazideglimepiridegliquidoneglisoxepidemetahexamidetolazamidetolbutamide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Metabolic acidosis contraindication 59455009
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Severe diarrhea contraindication 409587002
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Prolonged-Severe Nausea and Vomiting contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.31 acidic
pKa2 11.71 acidic
pKa3 12.9 acidic
pKa4 3.19 Basic
pKa5 0.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Kd 9.10 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
4018508 VUID
N0000146830 NUI
D00335 KEGG_DRUG
4018508 VANDF
C0017642 UMLSCUI
CHEBI:5384 CHEBI
CHEMBL1073 ChEMBL_ID
D005913 MESH_DESCRIPTOR_UI
DB01067 DRUGBANK_ID
6821 IUPHAR_LIGAND_ID
3090 INN_ID
X7WDT95N5C UNII
3478 PUBCHEM_CID
151822 RXNORM
4783 MMSL
574 MMSL
595 MMSL
d00246 MMSL
000913 NDDF
26124005 SNOMEDCT_US
387143009 SNOMEDCT_US
X7WDT95N5C INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
GlucotrolXL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0170 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 27 sections
GlucotrolXL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0174 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 27 sections
GlucotrolXL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0178 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 2.50 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 2.50 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0460 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0461 TABLET 10 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8407 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-8408 TABLET 10 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6637 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-192 TABLET 10 mg ORAL ANDA 12 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-193 TABLET 5 mg ORAL ANDA 12 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-220 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-221 TABLET 10 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 12634-729 TABLET 5 mg ORAL ANDA 26 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 12634-790 TABLET 10 mg ORAL ANDA 26 sections
GLIPIZIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-286 TABLET 5 mg ORAL ANDA 12 sections
GLIPIZIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-287 TABLET 10 mg ORAL ANDA 12 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 16714-894 TABLET, EXTENDED RELEASE 2.50 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 16714-895 TABLET, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 16714-896 TABLET, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 21695-469 TABLET 5 mg ORAL ANDA 12 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 21695-470 TABLET 10 mg ORAL ANDA 12 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 21695-894 TABLET, FILM COATED 5 mg ORAL ANDA 29 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 21695-967 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 23 sections
Glipizide and Metformin HCl HUMAN PRESCRIPTION DRUG LABEL 2 23155-115 TABLET, FILM COATED 2.50 mg ORAL ANDA 14 sections
Glipizide and Metformin HCl HUMAN PRESCRIPTION DRUG LABEL 2 23155-115 TABLET, FILM COATED 2.50 mg ORAL ANDA 14 sections
Glipizide and Metformin HCl HUMAN PRESCRIPTION DRUG LABEL 2 23155-116 TABLET, FILM COATED 2.50 mg ORAL ANDA 14 sections
Glipizide and Metformin HCl HUMAN PRESCRIPTION DRUG LABEL 2 23155-116 TABLET, FILM COATED 2.50 mg ORAL ANDA 14 sections